Synapse

← Atherosclerosis Plus

Papers in Atherosclerosis Plus

Page 3 · newest first

  1. Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trialAtherosclerosis Plus · 2024
  2. The effect of hydroxychloroquine on cholesterol synthesis depends on the profile of cholesterol metabolism. A controlled clinical studyAtherosclerosis Plus · 2024
  3. Treatment intensification with bempedoic acid to achieve LDL-C goal in patients with ASCVD: A simulation model using a real-world patient cohort in the USAtherosclerosis Plus · 2024
  4. Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023Atherosclerosis Plus · 2024
  5. Refined metabolite profiling in the collateral circulation of chronic total occlusion of coronary arteries: Insights from a metabolomics investigationAtherosclerosis Plus · 2024
  6. Changing from lipoprotein apheresis to evolocumab treatment lowers circulating levels of arachidonic acid and oxylipinsAtherosclerosis Plus · 2024
  7. Endothelial dysfunction and cardiovascular diseases in people living with HIV on specific highly active antiretroviral therapy regimen: A systematic review of clinical studiesAtherosclerosis Plus · 2024
  8. Associations of carotid atherosclerosis with cognitive function and brain health: Findings from a UK tri-ethnic cohort study (Southall and Brent Revisited)Atherosclerosis Plus · 2024
  9. The atorvastatin metabolite pattern in muscle tissue and blood plasma is associated with statin muscle side effects in patients with coronary heart disease; An exploratory case-control studyAtherosclerosis Plus · 2024
  10. Conditional deletion of Ccl2 in smooth muscle cells does not reduce early atherosclerosis in miceAtherosclerosis Plus · 2023
  11. Plasma lipids in Pseudoxanthoma Elasticum (PXE) patients: A comparative study with population-based reference values and Non-PXE controlsAtherosclerosis Plus · 2023
  12. Acute myocardial infarction preferentially alters low-abundant, long-chain unsaturated phospholipid and sphingolipid species in plasma high-density lipoprotein subpopulationsAtherosclerosis Plus · 2023
  13. CTCA in children with severe heterozygous familial hypercholesterolaemia: Screening for subclinical atherosclerosisAtherosclerosis Plus · 2023
  14. ITGB2 is a central hub-gene associated with inflammation and early fibro-atheroma development in a swine model of atherosclerosisAtherosclerosis Plus · 2023
  15. High-density lipoprotein cholesterol and multiple myeloma: A systematic review and meta-analysisAtherosclerosis Plus · 2023
  16. The LIPL study: Postprandial lipid profile, inflammation, and platelet activity in patients with chronic coronary syndromeAtherosclerosis Plus · 2023
  17. Prediabetes is an incremental risk factor for adverse cardiac events: A nationwide analysisAtherosclerosis Plus · 2023
  18. Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?Atherosclerosis Plus · 2023
  19. High-density lipoproteins and non-alcoholic fatty liver diseaseAtherosclerosis Plus · 2023
  20. The effect of hydroxychloroquine on cholesterol metabolism in statin treated patients after myocardial infarctionAtherosclerosis Plus · 2023
  21. Increased extracellular vesicles (EVs) related to T cell-mediated inflammation and vascular function in familial hypercholesterolemiaAtherosclerosis Plus · 2023
  22. The German CaRe high registry for familial hypercholesterolemia – Sex differences, treatment strategies, and target value attainmentAtherosclerosis Plus · 2023
  23. SARS-CoV-2 reinfection: Adding insult to dysfunctional endothelium in patients with atherosclerotic cardiovascular diseaseAtherosclerosis Plus · 2023
  24. Characteristics of peripheral blood cells are independently related to major adverse cardiovascular events after carotid endarterectomyAtherosclerosis Plus · 2023
  25. Fibronectin extra domain a limits liver dysfunction and protects mice during acute inflammationAtherosclerosis Plus · 2023
  26. Long term aortic arch plaque progression in older adultsAtherosclerosis Plus · 2023
  27. HDL and chronic kidney diseaseAtherosclerosis Plus · 2023
  28. Low HDL-c levels at admission are associated with greater severity and worse clinical outcomes in patients with COVID-19 diseaseAtherosclerosis Plus · 2023
  29. Young women with familial hypercholesterolemia have higher LDL-cholesterol burden than men: Novel data using repeated measurements during 12-years follow-upAtherosclerosis Plus · 2023
  30. Associations of urinary isoprostanes with measures of subclinical atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA)Atherosclerosis Plus · 2022
  31. Dendritic cell marker Clec4a4 deficiency limits atherosclerosis progressionAtherosclerosis Plus · 2022
  32. Lp(a) does not affect intima media thickness in hypercholesterolemic children –a retrospective cross sectional studyAtherosclerosis Plus · 2022
  33. Subclinical atherosclerosis determined by coronary artery calcium deposition in patients with clinical familial hypercholesterolemiaAtherosclerosis Plus · 2022
  34. Periostin contributes to the adventitial remodeling of atherosclerosis by activating adventitial fibroblastsAtherosclerosis Plus · 2022
  35. The circulating furin-cleaved/mature PCSK9 ratio has a potential prognostic significance in statin-naïve patients with acute ST elevation myocardial infarctionAtherosclerosis Plus · 2022
  36. TACE/ADAM17 substrates associate with ACS (Ep-CAM, HB-EGF) and follow-up MACE (TNFR1 and TNFR2)Atherosclerosis Plus · 2022
  37. Clinical characteristics and cardiovascular outcomes among young patients with acute myocardial infarction in Kerala, India: A secondary analysis of ACS QUIK trialAtherosclerosis Plus · 2022
  38. Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI studyAtherosclerosis Plus · 2022
  39. Smoking and diabetes attenuate beneficial effects of PSCK9 inhibitors on arterial wall properties in patients with very high lipoprotein (a) levelsAtherosclerosis Plus · 2022
  40. Polygenic risk score for hypercholesterolemia in a Brazilian familial hypercholesterolemia cohortAtherosclerosis Plus · 2022
  41. Novel protein-truncating variant in the APOB gene may protect from coronary artery disease and adverse cardiovascular eventsAtherosclerosis Plus · 2022
  42. Semaglutide treatment attenuates vessel remodelling in ApoE−/− mice following vascular injury and blood flow perturbationAtherosclerosis Plus · 2022
  43. Two novel variants in the lecithin:cholesterol acyltransferase gene resulted in classic LCAT deficiencyAtherosclerosis Plus · 2022
  44. A PCSK9 inhibitor induces a transient decrease in the neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in homozygous familial hypercholesterolemia patientsAtherosclerosis Plus · 2022
  45. Circular RNA expression profile of H2O2 induced ferroptosis model of human coronary artery endothelial cellsAtherosclerosis Plus · 2022
  46. Secular trends in serum lipid profiles in young adults in Norway, 2001-19Atherosclerosis Plus · 2022
  47. The NLRP3 inflammasome activation in subcutaneous, epicardial and pericardial adipose tissue in patients with coronary heart disease undergoing coronary by-pass surgeryAtherosclerosis Plus · 2022
  48. Lipids, lipoproteins and prevalence of familial hypercholesterolemia in the Faroe Islands – Results from a nationwide laboratory databaseAtherosclerosis Plus · 2022
  49. Atherosclerosis severity in patients with familial hypercholesterolemia: The role of T and B lymphocytesAtherosclerosis Plus · 2022
  50. Urine ketone bodies and adverse outcomes in patients with acute ischemic stroke or TIAAtherosclerosis Plus · 2022